|
|
| | AZITHROMYCIN-D3 Basic information |
| | AZITHROMYCIN-D3 Chemical Properties |
| Melting point | 125-1290C | | Boiling point | 822.105±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.184±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | -20°C Freezer, Under Inert Atmosphere | | solubility | Chloroform (Slightly, Sonicated), Methanol (Slightly) | | form | Solid | | pka | 13.278±0.70(predicted) | | color | White to Off-White | | EPA Substance Registry System | 1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-6-(methyl-d3)-11-[[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (163921-65-1) |
| | AZITHROMYCIN-D3 Usage And Synthesis |
| Description | Azithromycin-d3 is intended for use as an internal standard for the quantification of azithromycin (Item No. 15004) by GC- or LC-MS. Azithromycin is a macrolide antibiotic. It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively). It inhibits replication of severe acute respiratory coronavirus 2 (SARS-CoV-2), but not Middle East respiratory syndrome CoV (MERS-CoV), when used at concentrations of 5 and 10 μM. Azithromycin also decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in a mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg. Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections. | | Chemical Properties | White Solid | | Uses | AzithroMycin-d3 can be used as Semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial.;AzithroMycin-d3 can be intended for use as an internal standard for the quantification of Azithromycin by GC- or LC-mass spectrometry. | | IC 50 | Macrolide | | References | [1] M S KANATANI B J G. The new macrolides. Azithromycin and clarithromycin.[J]. The Western journal of medicine, 1994, 160 1: 31-37.
[2] D GIRARD. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.[J]. Journal of Antimicrobial Chemotherapy, 2005, 56 2: 365-371. DOI: 10.1093/jac/dki241
[3] AHMED MOSTAFA. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.[J]. ACS Applied Energy Materials, 2020. DOI: 10.3390/ph13120443
[4] ANASUYA PATEL. Azithromycin in Combination with Ceftriaxone Reduces Systemic Inflammation and Provides Survival Benefit in a Murine Model of Polymicrobial Sepsis.[J]. ACS Applied Energy Materials, 2018. DOI: 10.1128/aac.00752-18 |
| | AZITHROMYCIN-D3 Preparation Products And Raw materials |
|